Participants will receive vitamin C in addition to active comparator treatment:
Inpatients: IV Vitamin C (Sodium Ascorbate) 50mg/kg every 6hrs on day 1 followed by 100mg/kg every 6hrs (4x per day; 400mg/kg/day) for 7 days (average 28g/day; maximum dose of 50g/24hrs for those weighing more than 125kg). Can be converted to 1 gram three times per day PO on hospital discharge) Outpatients: Vitamin C Outpatient trial: 200mg/kg x1 IV, then 1 gram PO three times per day for 7 days;
Plus Active Comparator treatment:
Hydroxychloroquine Hydroxychloroquine 400mg PO twice a day for 1 day, followed by 200mg PO two times a day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days

Hydroxychloroquine Hydroxychloroquine 400mg PO twice a day for 1 day, followed by 200mg PO two times a day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days

COVID19

In addition to the active comparator, which is a combination of 2 drugs and 3 dietary supplements, the experimental treatment arm will also receive Vitamin C (intravenous or oral)

Vitamin C

Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements

Hydroxychloroquine

Azithromycin

Zinc Citrate

Vitamin D3

Vitamin B12

International ALLIANCE Study of Therapies to Prevent Progression of COVID-19

Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial: The International ALLIANCE Study

Composite measure: Change in severity and duration of symptoms

total number of days in hospital since admission

need for invasive mechanical ventilation or mortality within 15 days from enrolment

need for and number of days of invasive mechanical ventilation, in case of no need for mechanical ventilation: days=0

need for and number of days for humidified high-flow oxygen

need for and days of renal replacement therapy

need for and days of Extracorporeal support

National Institute of Integrative Medicine, Australia

Catholic Health Initiatives

randomized investigator-blinded controlled

Participants not blinded as they will know whether they are receiving the comparator vitamin c (either IVC) or oral in addition to treatments in the control group; outcomes assessor / investigators conducting statistical analysis will be blinded

Droperidol (Xomolix, Kyowa Kirin) 1.25 mg i.v. bolus

Arrhythmia, Droperidol

An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.

Droperidol Injectable Solution

Medical University of Gdansk

Gender Influence on Torsadogenic Actions of Droperidol.

Gender Influence on Torsadogenic Actions of Droperidol Used as Postoperative Nausea and Vomiting Prophylaxis.

Radoslaw Owczuk

Clinical Professor, Head of Department of Anaesthesiology and Intensive Care

Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes (active experimental) and normal saline 1ml intravenous push injection (placebo)

Ketorolac 30mg (1ml) intravenous push injection (active intervention) and Normal saline 50ml IVPB over 10 minutes (placebo)

Renal Colic

Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes x 1dose

Lidocaine

Ketorolac 30mg (1ml) intravenous push injection x 1dose

Ketorolac

The Brooklyn Hospital Center

Lidocaine vs Ketorolac for Management of Renal Colic in the Emergency Department

Lidocaine Versus Ketorolac for the Management of Renal Colic

Patient's perception of pain as described by the use of numeric rating scale (NRS) at 15 minutes after initial study interventions

incidence of arrhythmia (atrial fibrillation, ventricular tachycardia, ventricular fibrillation)

incidence of respiratory depression (respiratory rate less than 12bpm)

incidence of oxygen saturation less than 90%

the number of patients who consumed an adjuvant pain medication for analgesia.

This is a double-blind placebo-controlled randomized trial where blinding will be conducted and applied to the study investigator, physicians, and nursing staff providing care to the patient. An independent biostatistician will conduct a statistical analysis with blinded data. Only the pharmacists preparing the study interventions will be unblended to the study treatments. The pharmacists procuring the interventions will not be part of data collection or analysis.

ventricular fibrillation/uppköst

International ALLIANCE Study of Therapies to Prevent Progression of COVID-19

Gender Influence on Torsadogenic Actions of Droperidol.

Lidocaine vs Ketorolac for Management of Renal Colic in the Emergency Department

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum